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In disease-endemic areas, preventive chemotherapy with two orally 
administered anthelminthic drugs, praziquantel and albendazole, forms the 
foundation of control of schistosomiasis and soil-transmitted helminthiasis. 
Where diseases overlap, these two drugs are typically co-administered 
simultaneously, although albendazole is often interchangeable with 
mebendazole. With a supportive pharmaceutical industry that donates 
drugs and a strong international partnership that mobilizes donor funds for 
drug delivery, scale-up of treatment in school-aged children has expanded 
significantly in line with the WHO 2012–2020 strategic plan. Other high-risk 
groups, such as pre-school-aged children, are now benefiting from 
deworming campaigns conducted alongside other childhood interventions, 
such as vaccination, less so, however, for schistosomiasis as infections in 
this age class are not being treated. Looking to the future, maintaining 
an effective drug distribution and reporting system that regularly checks 
anthelminthic performance alongside documenting improvements in child 
health are essential for the long-term success of preventive chemotherapy 
with praziquantel and albendazole.
Keywords: ascariasis • deworming • hookworm • intestinal schistosomiasis  
• trichuriasis • urogenital schistosomiasis 
Background & introducing preventive chemotherapy
With the fruition of international advocacy to highlight the importance of diseases 
within neglected people of the world, a total of 17 neglected tropical diseases (NTDs) 
are now recognized. These are grouped into two major categories, each with clear 
intervention strategies as developed by the WHO. Collectively NTDs account for a 
significant global burden of disease as measured by the disability-adjusted-life-year 
that was recently revised to include outcomes directly attributable to them, namely, 
NTD-related anemia [1]. Whilst not directly equivalent with HIV/AIDS, tuberculosis 
and malaria, the so-called ‘big three’, NTDs are perhaps of greatest renown for impair-
ing childhood development, inducing disfigurement and social stigmatization [2]. 
Moreover they perpetuate the cycle of poverty for both individuals and communities 
afflicted by them. In sharp contrast to control of the ‘big three’ for which interventions 
at the individual level are typically considered expensive, interventions against several 
NTDs caused by nematodes, namely, lymphatic filariasis (elephantiasis), onchocer-
ciasis (river blindness), soil-transmitted helminthiasis (STH), or trematodes, namely 
schistosomiasis (Bilharzia), are eminently affordable [3]. Indeed, it makes sound eco-
nomic sense at the public health level, with rapid-impact health packages that attempt 
to work in an integrated manner [4]. Furthermore control of schistosomiasis and 
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STH is also thought to impart benefits on the prognosis 
of those with HIV by retarding progression onto AIDS 
(see below) [5].
A uniting feature of control of these NTDs is promo-
tion of better and regular access to existing anthelminthic 
treatment(s), alternatively known as dewormers, which is 
the foundation for abating present and future morbidity 
[2]. This works by either attempting to eliminate para-
site transmission, for example lymphatic filariasis, or to 
depress within-host worm burdens on a regular basis, for 
example schistosomiasis and STH [6,7]. Thus the termi-
nology of preventive chemotherapy for human helminthi-
asis was coined and was later endorsed by World Health 
Assembly resolutions beginning with WHA54.19 in 2001 
encouraging scale-up to reach stipulated drug coverage 
targets [8,9]. Just over 10 years later, the 2012 London 
Declaration on Neglected Tropical Diseases provided a 
further advocacy platform where a number of leading 
international donors and agencies formally agreed to sus-
tain, expand and extend drug access programs in line with 
evolving preventive chemotherapy (PC) strategies [2,10].
Moreover, this declaration ensured the necessary sup-
ply of drugs gratis and other interventions to help con-
trol schistosomiasis, STH, onchocerciasis and lymphatic 
filariasis by 2020 as envisaged within the 2012–2020 
WHO Strategic Plan [7]. Thus with a simple drug arma-
mentarium consisting of ivermectin (IVM), diethylcar-
bamazine citrate (DEC), albendazole (ALB), meben-
dazole (MEB) and praziquantel (PZQ), a tool ready 
method for large-scale control by PC with integrated 
co-delivery of treatments was feasible [8,11]. A list of com-
mitments secured at this meeting can be found at [101]. 
Thus with a supportive pharmaceutical industry that 
donates drugs and a strong international partnership of 
advocates that mobilizes donor funds for drug delivery, 
a strong international treatment platform fostered the 
scale-up and delivery of treatments to afflicted commu-
nities throughout the world, see Figure 1. Whilst PC is 
the foundation for control of schistosomiasis and STH 
[10], other interventions that encourage inter-sectoral 
collaboration should not be eclipsed [2]. Those that 
enhance access to better sanitation, safe water provi-
sion, behavioral change and control of intermediate 
hosts (schistosomiasis), are each highlighted in the 
WHO 2012–2020 strategic plan and known to syner-
gize and bolster PC measures [7,12]. For schistosomiasis 
and STH this is particularly pertinent for the drugs 
used in PC do not safeguard against re-infection, so re-
parasitism after deworming can follow quickly should 
local conditions be conducive. Thus PC can be seen 
as a long-term commitment to the provision of short-
term deworming medications until sufficient evidence 
is accrued for stopping decisions, namely cessation of 
periodic treatment(s), to be taken. 
 ■ Schistosomiasis & STH
Schistosomiasis and STH are caused by several different 
species of trematode and nematode worm respectively 
that have some commonalities in the mode of trans-
mission and mechanism of environmental contamina-
tion [13]. Table 1 summarizes some of the more pertinent 
features of the epidemiology of these parasites, noting 
that there are two forms of schistosomiasis, urogenital 
and intestinal, which can occur alone or in combination 
with any or all of the listed STHs. 
Urogenital schistosomiasis is now the preferred 
terminology rather than urinary schistosomiasis as 
used previously. This is in recognition of the detri-
mental impact of the disease on genitalia and future 
reproductive health, particularly in girls with female 
genital schistosomiasis (FGS) [14,15]. Recent research 
on FGS has revealed the strong link with HIV and 
looking to the future, control of FGS should feature 
within HIV campaigns equally as much as control of 
sexually transmitted infections [16]. The latter diseases 
are more well-known risk factors in HIV public health 
campaigns. In terms of NTD biology, the foremost 
difference between trematodes and nematodes is that 
the schistosomes require an intermediate snail host to 
complete their lifecycle whereas gastrointestinal nema-
todes do not [17]. All, however, flourish by poor sanita-
tion, whereby parasite eggs reach the environment in 
urine (Schistosoma haematobium) or feces (Schistosoma 
mansoni, Ascaris lumbricoides, Trichuris trichiura, 
hookworm) from infected hosts. Recent research has 
also highlighted the zoonotic potential of several of 
these worms highlighting that ‘one health’ strategies of 
control should be considered alongside PC [7].
More broadly, where there is poor sanitation and 
hygiene, the global numbers of people infected or at risk 
of infection with schistosomiasis and STH are astound-
ing. In 2011 for example, it was estimated that world-
wide 112 million school-aged children (SAC) lived in 
high-risk areas for schistosomiasis, while 875 million 
children lived in high-risk areas for STH, with 30% 
of these being children <5 years of age, that is, the pre-
school-aged children (preSAC) [18]. There are as yet 
no precise global estimates of the numbers of children 
presently infected with two or more of these parasites, 
yet these unknown proportions likely exacerbate the 
known detrimental effects of worm infection on quality 
of life, childhood growth and cognitive development 
[19,20]; another shortcoming of the disability-adjusted-
life-year is quantification of these cumulative effects. 
Indeed, such risk maps are at best underestimates of 
the true distribution of infection owing to the short-
coming of present diagnostic methods used to quantify 
the prevalence and intensity of infections across this 
vast geographical landscape, these ambiguities likely 
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confounded the studies within the recent Cochrane 
Review on school-based deworming and educational 
performance [21–23] and engendered debate [24]. 
 ■ Combined diagnosis & foundation for 
cotreatment
Whilst there are a variety of diagnostic tools available 
to detect active infections of schistosomiasis and STH, 
spanning antigen-antibody-DNA methodologies, the 
most pragmatic methods, as advocated by the WHO, 
include the use of classical parasitological methods 
undertaken upon a sample of the local children [25,26]. 
Here, a trained microscopist detects parasite eggs in 
excreta by simple filtration and smear methodologies. 
Preparations from stool or urine are then visualized by 
compound microscopy at ×100 or ×400 magnification; 
egg tallies of encountered helminths are recorded then 
expressed as an eggs per gram (epg) of feces or per 10 ml 
of urine. Such enumerations are with the firm inten-
tions to compare the severity of disease(s) from loca-
tion to location. In so doing, rational decisions for the 
prioritization of control can be taken. 
Diagnostic exceptions include the use of red-
urine questionnaires for the detection of urogenital 
A
B
<1 million
1–4.9 million
5–19.9 million
20–99.9 million
>100 million
Not applicable
Data not available
No PC required
To be defined
Figure 1. Global distribution of (A) schistosomiasis and (B) soil-transmitted helminthiasis with estimated needs for preventive 
chemotherapy. 
PC: Preventive chemotherapy. 
Reproduced with permission from [105] © WHO (2013). 
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schistosomiasis, where by interviewers (typically teach-
ers) pose a suite of questions to the child (interviewee) 
[11]. Since visible blood in urine (macrohematuria) is a 
pathognomonic sign of active infection, especially in 
boys, this is an accepted method to infer local prevalence 
of disease (Table 2). Although red-urine questionnaires 
are not particularly useful in mapping disease distribu-
tions where there has been previous distribution of PZQ, 
recourse to chemical reagent strips that detect microhe-
maturia is more insightful. 
For parasitic ova found in the feces, the single Kato-
Katz thick smear is the field-operational ‘gold standard’. 
In essence, 41.7 mg of stool is partially purified by size 
selection through a metal or nylon sieve of 200–300 µm 
pore size, then smeared on a glass slide and inspected at 
×100 magnification [11]. This amount of stool is typi-
cally sufficient to detect eggs shed from adult female 
worms found in or around the intestine. As S. haemato-
bium resides in the vasculature surrounding the vesicle 
plexus, in order to detect of urogenital schistosomiasis 
10 ml of urine, as collected mid-morning, is filtered by 
plastic syringe through a nylon membrane of 10–30 µm 
pore size. This filter retains schistosome eggs, and is 
then inspected at ×100 magnification [11]. Whilst effec-
tive for use in this field, there are several short-comings 
of these methods, which typically center around the 
low diagnostic sensitivity of methods when infections 
are perceived as ‘light’, namely when there are only a 
Table 1. Selected epidemiological features and anthelminthic drugs for control of schistosomiasis and soil-transmitted 
helminthiasis.
Subtype Species Mode of parasite entry and exit Treatment by MDA Alternative medications†
Schistosomiasis
Urogenital Schistosoma 
haematobium
Water-borne, larval stages 
(cercariae) emerging from 
infected snails penetrate intact 
skin upon direct contact
PZQ (in 600-mg tablets) donated 
by Merck-KGaA is effective against 
adult worms but not immature 
worms
Metrifonate‡ (in 100-mg 
tablets) is active against 
Schistosoma haematobium 
at 7.5 mg/kg dosing 
on three occasions at 
intervals of 2 weeks
Intestinal§ Schistosoma 
mansoni
Schistosoma 
japonicum
Adult worm pairs reside in the 
blood vasculature and release 
copious amounts of eggs in 
urine or feces
Single dose of either 40 or 
60 mg/kg by bodyweight as 
estimated by weighing scales or 
height pole
Licensed for children >4 years old
Oxamniquine¶ (in 250-mg 
capsules) is active against 
S. mansoni at 30 mg/kg in 
two divided doses
Soil-transmitted helminthiasis#
Ascariasis Ascaris
lumbricoides
Terrestrial, ingestion of 
parasite eggs from fecal-oral 
contamination
ALB†† (in 400 mg tablets) donated 
by GlaxoSmithKline single dose 
treatment for children aged 
>2 years of age, with a half tablet 
for children aged between 1 and 
2 years
Levamisole (in 50 mg 
tablets) single-dose 
treatment at 2.5 mg/kg
Trichuriasis Trichuris
Trichiura
Adult worms reside within the 
lumen of the bowel releasing 
eggs in feces
– Piperazine (in 500 mg 
tablets) in single dose at 
75 mg/kg to a maximum 
of 3.5 g in adults and 
2.5 g in children between 
2–12 years of age
Hookworm Necator
americanus
Ancylostoma
duodenale
Terrestrial, larval stages (L3) 
penetrate intact skin
MEB (in 500 mg tablets) donated 
by Johnson & Johnson, single dose 
treatment for children >1 year old
Pyrantel pamoate (in 
250 mg tablets) in a single 
dose of 10 mg/kg
†Used in case-by-case settings rather than in preventive chemotherapy. 
‡No longer commercially produced. 
§There are three other species that cause intestinal disease: Schistosoma intercalatum, Schistosoma guineensis, Schistosoma mekongi but are of less global importance. 
¶Sporadic production in Brazil alone. 
#Omitting Strongyloides stercoralis. 
††Broad spectrum but less effective against trichuriasis and hookworm. 
ALB: Albendazole; MDA: Mass drug administration; MEB: Mebendazole; PZQ: Praziquantel.
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handful (or fewer) eggs being shed by the host. To raise 
sensitivity, multiple stool and urine specimens taken 
over consecutive days may increase sensitivity but this 
incurs increased costs of logistics and staff time, which 
are often the limiting factors when numerous locations 
are to be visited for disease surveillance. 
Estimating the prevalence of disease locally is impor-
tant as there are thresholds in prevalence, as recom-
mended by WHO [6,7], that trigger different treatment 
strategies (Table 2). These are based on data from surveys 
in which a single specimen is taken and takes into con-
sideration the sensitivity of the diagnostic method used, 
for example it is recognized that when a 30% preva-
lence of STH is estimated in a population with a single 
Kato-Katz, the ‘real’ STH prevalence estimated with 
a more sensitive method would probably correspond 
to 40–45%; the WHO treatment strategies take into 
consideration these diagnostic biases. Across a disease 
landscape, the diagnostic coverage by location and per-
formance of these methods is a working compromise 
between available resources and specific surveillance 
needs [27,28]. Care needs to be taken on interpretation of 
‘risk maps’ that are derived from such information that is 
inherently confounded by the lack of diagnostic precision 
and insufficient density of sampled locations [29].
 ■ Unavoidable operational compromises
At a programmatic level, there are two major uses of these 
diagnostic tools [4]. First is for general detection of disease 
within communities (rather than individuals per se) to 
help build a ‘working’ local distribution map attempting 
to record the endemicity of each disease. Second these 
methods are used to assess the efficacy of deworming 
treatment(s), where programs seek to measure either 
short-term impact, 24–28 days after treatment, namely 
drug pharmacodynamics [30], or long-term impact over 
Table 2. WHO recommended treatment strategy for schistosomiasis and soil-transmitted helminthiasis.
Category Baseline prevalence among SAC Action to be taken with PZQ or ALB/MEB†
High-risk community
Schistosomiasis ≥50% by parasitological methods‡ 
(intestinal and urogenital 
schistosomiasis);
Or ≥30% by questionnaire for history 
of haematuria
Treat all SAC
(enrolled and not enrolled) 
once a year
Also treat adults considered to be at 
risk (from special groups§ to entire 
communities living in endemic areas)
STH 50% by parasitological inspection 
methods of fecal material
Treat all SAC twice a year Treat preSAC and women of child-bearing 
age twice a year
Moderate-risk community
Schistosomiasis ≥10% but <50% by parasitological 
methods
(intestinal and urogenital 
schistosomiasis);
Or <30% by questionnaire for history 
of haematuria
Treat all SAC (enrolled and 
not enrolled) once every 
2 years
Also treat adults considered to be at risk 
(special groups§ only)
STH ≥20% by <50% by parasitological 
inspection methods of fecal material
Treat all SAC once a year Treat preSAC and women of child-bearing 
age once a year
Low-risk community
Schistosomiasis <10% by parasitological methods
(intestinal and urogenital 
schistosomiasis)
Treat all school-age 
children (enrolled and not 
enrolled) twice during their 
primary schooling age 
(e.g., once on entry and 
once on exit)
PZQ should be available in dispensaries 
and clinics for treatment of suspected 
cases
STH <20% by parasitological inspection 
methods of fecal material
Case-by-case treatment 
of SAC
Case-by-case treatment of preSAC and 
women of child bearing age
†Equivalent to: High-risk community: All school-age children and adults require preventive chemotherapy annually; Moderate-risk community: 50% of school-age 
children and 20% of adults require preventive chemotherapy annually; Low-risk community: 33% of school-age children require preventive chemotherapy annually. 
‡For urogenital schistosomiasis, detection of hematuria by chemical reagent strips gives results equivalent to those determined by urine filtration. 
§Special groups: Pregnant and lactating women; groups with occupations involving contact with infested water such as fishermen, farmers, irrigation workers or women 
in their domestic tasks, to entire communities living in endemic areas. 
ALB: Albendazole; MEB: Mebendazole; PZQ: Praziquantel; SAC: School-aged children; STH: Soil-transmitted helminthiasis.
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more extended timeframes, years and longer, between 
treatments that typically precede consecutive PC treat-
ment cycles [31]. The former is typically expressed in 
terms of cure rate (CR) and egg reduction rate (ERR) 
and has been used widely in the literature to monitor the 
performance of PZQ and ALB. The latter is reported as 
changes in disease prevalence and intensity of infections 
in comparison to that prior to intervention [32,33]. 
On the whole, short-term drug performance of 
PZQ and ALB is typically good with parasitological 
CRs often in excess of 75% [34]. However, there can 
be exceptions, for example low cure rates <50% in 
Senegal, preSAC children with intestinal schistoso-
miasis [35] or STH [36], respectively. Following recent 
discussions in WHO-Geneva and investigations of 
the dynamics of these metrics, it is now considered 
that ERR is thought to be a better estimate of drug 
performance, which typically is approximately >85% 
[37,38]. A central difficulty in measuring the short-term 
impact of anthelminthic with CR is in the nature of 
worm egg excretion itself and that fecal epgs are often 
over-dispersed across an endemic community, namely, 
some individuals have inordinately higher epgs than 
others, thereby ‘skewing’ leads to an underestimate 
of cure [22]. 
For example, whilst there may be reductions of sev-
eral thousand shed parasite eggs to only a handful, these 
non-negative values represent ‘treatment failures’, when 
CR is used, ERR on the other hand is not influenced as 
much by the overdispersed distribution of eggs in the 
population, especially if a geometric mean epg is used 
[37,38]. A central tenet of PC is to reduce worm burdens, 
and it is perhaps unrealistic to expect a complete cure 
if sampled children range with worm burdens ranging 
in five or more orders of magnitude, namely, 10, 100, 
1000, 10000+. Since drugs are given out as single dose 
and not ‘dose-ranged’ or ‘weighted’ towards increasing 
parasite densities, thus fixed dosing at the heavier inten-
sity of infections is likely sub-curative if drug uptake 
levels are initially swamped by masses of worms. The 
merits between using actual egg intensities or thresh-
old classifications has been debated elsewhere, but for 
schistosomiasis, where the disease is typically resultant 
from the accumulation of eggs trapped in tissues [17], it 
should be noted that any significant reductions in egg 
production can be considered a successful outcome of 
PZQ treatment. Changes in disease prevalence after 
treatment are often difficult to predict and are deter-
mined empirically. Recent studies have shown that re-
infection dynamics are often place-specific owing to 
the inherent heterogeneity in a myriad of causal factors 
that vary from location-to-location, for example levels of 
sanitation and environmental contamination amongst 
others [11].
 ■ Rationale drug delivery across a disease 
landscape
The fundamental raison d’etre for mapping is to set and 
to guide on-the-ground intervention zones [4,11]. There are 
informal WHO documents that attempt to streamline 
this surveillance task in terms of number of locations to 
be sampled, typically primary schools (that act as conve-
nient geographical anchor points) [39,40], and the numbers 
of children to be screened at each location, usually 60 or 
less [41]. It is beyond the scope of this review to address the 
merits of lot quality assurance sampling (LQAS) versus 
fixed sample sizes for estimation of the local prevalence of 
disease, however, each method attempts to classify a loca-
tion as high, moderate and low-risk of disease (Table 2). 
Aiming to maximize the geographical knowledge of dis-
ease endemicity between nonsampled points, namely to 
bolster field sampling that is logistically challenging, has 
seen the rise of remotely sensed environmental data with 
spatial modeling and risk prediction. Although creation 
of spatially explicit databases is important [102], the accu-
racy and reliability of predictive disease maps derived 
from it to guide PC still engenders debate [42]. Foremost, 
is that although chronic, these diseases are prone to the 
dynamics of environmental and anthropogenic changes, 
thus spatial-risk predictions need regular updating and 
validation to remain informative through time before 
becoming locally obsolete [40,41]. 
Nonetheless, evidence-based decisions taken upon the 
known or likely distribution of schistosomiasis and STH 
across a countries’ landscape is vital to setting and fore-
casting anthelminthic drug requirements of PZQ and 
ALB or MEB [6,43]. This is at the onset of a national con-
trol program implementing PC as part of its strategic plan 
and temporal road map of possible interventions to be 
taken through time [44]. Here, it should also be noted that 
surveillance of schistosomiasis and STH does not operate 
alone and for it is, or should be, incorporated within the 
geographical landscape for surveillance of other NTDs, 
for example for lymphatic filariasis and onchoceriasis 
[29,45]. This is because for PC treatment associated with 
the latter two diseases, impacts upon STH, for IVM and 
ALB taken individually or combined, has tangible impact 
upon each nematode species [46]. Indeed, the algorithm 
for PC is illustrated in Figure 2, in which umbrella treat-
ment decisions for lymphatic filariasis and onchocerciasis 
are part of the treatment decisions tree.
These PC treatment algorithms mesh with the preva-
lence threshold guidelines of Table 2, such that in high 
prevalence areas of schistosomiasis, STH and lymphatic 
filariasis, a SAC can expect to receive two biannual 
doses of ALB, each co-administered with IVM (one for 
lymphatic filariasis treatment) or PZQ (one with schis-
tosomiasis cotreatment) spaced apart by approximately 
6 months. The exact timing of these treatments during 
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the calendar year; however, can vary 
due to logistical constraints that may 
delay the drug delivery operations. 
Indeed, it can be challenging for 
national control program managers to 
work in a harmonized way [47] when 
there have been global shortages in 
drugs and difficulties in international 
shipping [48]. Foremost for PZQ, for 
example, the present demand for the 
drug currently outstrips production 
five-fold. This is thought to ease in 
forthcoming years as the Merck-
KGaA annual donation of 250 mil-
lion tablets is realized.
 ■ PreSAC have equitable access 
to ALB but not PZQ 
A glaring exception in this cotreat-
ment algorithm is the drug delivery 
situation in preSAC. Until 2002, 
WHO did not recommend large-
scale treatment interventions with 
ALB or MEB to preSAC under the 
age of 24 months, yet infections in 
this age class were previously known, 
in particular for ascariasis and trichuriasis [49]. These 
infections can be acquired soon after birth being linked 
by the correlated epidemiology of mother and child. An 
expert meeting was held in April 2002 at WHO-Geneva 
to discuss access of preSAC to anthelminthics; at the 
same time discussions also centered on the use of PZQ 
in pregnant women, which was then contraindicated in 
drug licensing [6]. Upon consideration of all available 
evidence the meeting concluded that preSAC children 
should be provided with ALB or MEB on a regular basis, 
reasons for this are discussed below [11]. Today treatment 
of preSAC with ALB or MEB has been a much under 
acknowledged success of PC campaigns. In 2009 for 
example, over 50 countries reported data with a total 
of 109.7 million preSAC treated during immunization 
campaigns, vitamin A supplementation, child-health 
days and elimination campaigns for lymphatic filaria-
sis. Notably in Africa, of the 42 countries requiring PC, 
25 reported data in 2009 with more than 50 million 
preSAC children corresponding to a regional treatment 
coverage of >46% [6].
The situation for treatment of preSAC with schisto-
somiasis is less than satisfactory and mirrors the situa-
tion found in STH treatment just over a decade ago. 
In high transmission areas it is clear that preSAC can 
have active schistosomiasis acquired by passive water 
contact, namely in domestic bathing water [50–55]. Pres-
ently children who are patently infected have little or no 
access to PZQ and this was discussed at length again at 
WHO-Geneva in September 2010. After reviewing new 
epidemiological information it was acknowledged that 
preSAC were a high risk group, particularly vulnerable 
to infection and that broken and (or) crushed tablets of 
PZQ could be used for treatment on a case-by-case basis 
[56]. Large-scale PC campaigns with PZQ in this age 
class were considered a little premature until a suitable 
pediatric formulation of PZQ was produced. With the 
formation of a new public-private-partnership, a phar-
maceutical consortium has undertaken the task of devel-
oping an orally dispersible tablet, with taste masking, 
which is presently in pre-clinical evaluation [52]. None-
theless the burden of schistosomiasis in preSAC remains 
unchecked by PC as such infected children do not have 
immediate access to PZQ but they are now recognized 
as a high-risk group in need of further attention [7]. 
A focus on PZQ & ALB
The chemical structure of PZQ is shown in Figure 3A, 
representing 2-(cyclohexylcarbonyl)-1,2,3,5,7,11b-
hexahydro-4H-pyrazino[2,1-a]isoquinoline-4-one [57]. 
Pertinent features of this drug are listed in Table 3 [58] 
and reviewed by Doenhoff et al. [59]. PZQ is a racemate 
[60] of dextro and laevo-isomers and marketed as Bil-
tricide® with a drug licensing schedule of oral dosing 
at either 40 or 60 mg/kg bodyweight for adults and 
children over 4 years of age and active against all species 
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Figure 2. Integrated preventive chemotherapy by mass drug administration as 
determined by the endemic landscape of selected neglected tropical diseases. 
If the area is characterized by lymphatic filariasis then mass drug administration with 
ivermectin/diethylcarbamazine citrate and albendazole is scheduled. Other diseases are 
nested within this treatment algorithm (blue tick: recommended as best option). 
ALB: Albendazole; DEC: Diethylcarbamazine citrate; IVM: Ivermectin; MDA: Mass drug 
administration; PZQ: Praziquantel; STH: Soil-transmitted helminthiasis. 
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of schistosome [61–63]. It is perhaps surprising that there 
are no pharmacokinetic studies in SAC or preSAC with 
all available information extrapolated from studies in 
adults [64,65]. It is known that intake of food enhances 
the drug plasma levels two–five-times, and bioavail-
ability between brands of PZQ can differ [66]. Adults 
with liver disease (i.e., intestinal schistosomiasis) have 
different levels and duration of PZQ in plasma, presum-
ably due to changes in levels of the cytochrome P450 
detoxification system [67]. Plasma levels are also known 
to change with co-administration of ALB [68], the latter 
drug and metabolites thereof is known to increase, but 
the impact of PZQ on ALB levels is much greater than 
that of the reverse, namely impact of ALB on PZQ [69]. 
Considered a rather cumbersome oblong tablet of 
600 mg, scored in half- or quarter-tablet units, the med-
ication remained relatively expensive until off-patent 
production by generic manufacturers reduced the price 
to less than US$0.10, making national PC campaigns 
affordable from 2002 with seed financial encourage-
ment by the Bill & Melinda Gates Foundation, as sup-
ported by the Schistosomiasis Control Initiative, UK. 
After the London Declaration, Merck-KGaA has now 
committed in its Merck Praziquantel Donation Pro-
gramme to supply 250 million tablets each year gratis. 
Whilst an important and generous step, it is not clear 
how commercial generic producers will respond to this 
mixed market of donation and retail as the 250 million 
tablet donation is ring-fenced for SAC. 
An important omission is that adults and preSAC 
are not factored into this donated drug supply. Even 
so, any donated or purchased drugs will still require 
aid budgets to support their delivery and reporting of 
treatment coverage during on-the-ground operations. 
Whilst major implementation agencies of SCI, UK and 
Research Triangle Institute, USA with ICOSA see [103] 
and ENVISION [104] campaigns have secured funds for 
scale-up, new obstacles to PC arise, such as erosion of 
adherence to treatment due to concerns of drug-induced 
side effects, for example emesis, which can discourage 
the treatment of others [62]. This is a nontrivial matter, as 
there are several instances when rural communities have 
come to reject these well-meaning health interventions, 
even when carefully planned [70].
The chemical structure of ALB is shown in Figure 3B, 
representing methyl 5-(propylthio)-2-benzimidazolecar-
bamate, a benzimidazole similar in structure to MED 
and thiabendazole. Pertinent features of this drug are 
listed in Table 3 [58]. As donated by GlaxoSmithKline 
(Brentford, UK), ALB is manufactured in an orange fla-
vored chewable circular 400-mg tablet. A recent study has 
further investigated the interactions between PZQ and 
ALB in adult volunteers [68]. Upon entering the blood the 
drug is metabolized to albendazole sulfoxide but unme-
tabolized ALB is directly effective against nematodes in 
the alimentary tract [71,72]. There is evidence that such 
nematodes, with their own cytochrome P450 enzymes, 
metabolize ALB to albendazole sulfoxide, indicating that 
it is probably a combination of these two drug phenom-
ena [58]. The important message is that ALB does not 
need to enter the bloodstream to be active on intestinal 
nematodes, whereas its absorption is necessary for treat-
ment of systemic nematodes or cestodes such as Wucher-
eria bancrofti or Taenia solium, respectively.  Benzimid-
azole metabolism, like PZQ, depends on oxidation by 
suite of cytochrome P450s in the liver. The action of 
ALB is known and interferes with the polymerization of 
b-tubulin fibers, with some evidence of genetic mutants 
that have diminished susceptibility to ALB [73,74]. 
Practicalities on PZQ & ALB cotreatment
The onsite requirements for treatment of SAC children 
for schistosomiasis and STH, such as treatment regis-
ters, potable water, have been recently described else-
where [75,76], with seminal studies on cotreatment by 
Olds et al. [31]. Key features of treatment-in-action are 
shown in Figure 4. The safety of cotreatment has been 
assessed in a variety of papers in different endemic set-
tings but cannot be considered exhaustive in comparison 
to the scale of operations where millions are treated [77,78]. 
Transitory side effects are known that resolve within 
24 h dosing to occur but these are not in excess of either 
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Figure 3. Chemical structures for (A) praziquantel and (B) albendazole. 
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Figure 4. Treatment at the school site in action. (A) Class sensitization 
of Liberian children to receive treatment and (B) administration of 
cotreatment.
drug when administered alone [78,79]. Other features of 
cotreatment worthy of discussion here relate to dosing 
and warrant some discussion. The key discriminating 
feature between the two drugs is the weight–height-dose 
relationship for PZQ and age-dose relationship for ALB 
in children aged 12–24 months and older, with Figure 5 
attempting to encapsulate these divisions. Foremost is 
that PZQ is administered by bodyweight at the lower 
standard 40 mg/kg dosing. 
For preSAC it is likely that this 40 mg/kg is satis-
factory in light of recent pharmacodynamic studies 
undertaken in Uganda in 2012 and 2013 [Bustinduy AL, 
Waterhouse D, Kabatereine NB, Ward S, Stothard JR. First phar-
macokinetic profiles of plasma levels of (+/-)praziquantel and 
associated pharmacodynamics in pre-school children: inves-
tigation drug administration at 40 or 60 mg/kg dosings (2014), 
Manuscript in preparation], which have abated initial con-
cerns that 40 mg/kg might have been too high following 
generic extrapolations of adult dosing into the pediatric 
settings [80]. It should be noted that a single 600 mg 
oblong tablet is towards the largest range of size that can 
be safely tolerated in the small mouths of children, so for 
preSAC the tablet can be crushed or broken into more 
acceptable sizes and often administered with a flavored 
drink to mask its bitter taste. This of course may alter 
its pharmacokinetics but liquid formulations of PZQ 
have been shown to be nonsuperior to the crushed tablet 
alternative. Where weight scales are lacking, an extended 
dosing pole or treatment stick has been developed to 
administer tablets on the basis of height, since there is 
a strong biometric relationship with weight [35,81]. The 
smallest possible tablet division is 150 mg owing to exist-
ing scoring [82]. Due to this, dosing by age has been 
explored in younger children in 150 mg increments that 
might provide an alternative to height-based dosing in 
children aged 6 months and over, which are typically 
underneath the 60-cm height threshold [82]. Higher stan-
dard dosing of 60 mg/kg is possible but as of yet there is 
no height pole developed for this range.
The situation for ALB dosing is much more straightfor-
ward. Adults, SAC and the majority of preSAC children 
receive a single tablet alone. Owing to slight concerns of 
drug toxicity in the very young child, in children aged 
between 12 and 24 months a half-tablet is administered 
and children younger than one year are presently excluded 
but can be treated on a case-by-case basis contingent upon 
Table 3. Essential information on praziquantel and albendazole.
PZQ (CAS: 55268-74-1; MW 312.3) ALB (CAS: 54965-21-8; NW: 265.34)
Formulation
 ■ Equimolar racement of R-(-)-PZQ (levorotated, 
L-PZQ) and S-(+)-PZQ (dextrorotated, D-PZQ). The 
S-(+)-PZQ form confers the unusually bitter taste
 ■ 600-mg tablets are usually scored into 150 mg or 
300-mg tablet divisions
 ■ Approximately 80% of the dose is excreted in the 
urine within 24 h
 ■ Typically in 400-mg orange flavored chewable tablets with 200-mg division
 ■ ALB is typically considered a prodrug for it remains inactive until upon 
absorption and is then quickly oxidized by extensive first pass metabolism in 
the liver to the active metabolite ASOX, which is further metabolized into the 
inactive ASON
 ■ Although active in the bowel lumen, it is thought that worms metabolise ALB 
into ASOX by their own cytochrome P450s
Mode of action and detoxification
 ■ Absorption is increased substantially with ingestion 
of carbohydrate or fatty food items
 ■ R-(-)- praziquantel and first pass metabolite (trans-4-
hydroxypraziquantel, (-)-(R)-4-OHPZQ) active against 
adult worm tegument interfering with membrane 
bound calcium channels, predominately on male 
worms
 ■ Metabolic detoxification depends on cytochrome 
P450s in particular CYP3A4
 ■ Absorption is increased substantially with ingestion of carbohydrate or fatty 
food items
 ■ ASOX interferes with parasite b-tubulin molecules that leads to loss of 
cytoplasmic microtubules, which impairs glucose uptake and leads to 
exhaustion and death. Secondary effects likely include inhibition of fumarate 
reductase
 ■ Metabolic activation and detoxification depend on cytochrome P450s in 
particular CYP1A1 and CYP3A4
ALB: Albendazole; ASON: Albendazole sulfone; ASOX: Albendazole sulfoxide; PZQ: Praziquantel.
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medical discretion. In contrast, MEB (500 mg) can be 
administered across all preSAC and in so doing simplifies 
even further the cotreatment regime for STH [6].
■ Reporting treatment coverage
A key feature that needs to be captured in PC is reported 
treatment coverage and also any side effects and(or) 
severe adverse events [83]. These are frequently tran-
sient resolving within 24 h after treatment and typi-
cally encompass nausea, abdominal discomfort and 
emesis, however, more severe reactions are known such 
as anaphylaxis, especially in locations where infection 
intensities are very high [37]. Fear of such events in a 
community can lead to reduced adherence with treat-
ment that is particularly unfortunate as it is often in 
these locations where treatments are 
most needed. At the lowest levels, 
drug administration and cover-
age is usually recorded by pen and 
paper in a treatment register book-
let [84]. Within a school-based treat-
ment campaign registers are simply 
grouped by class and often have 
additional space to record treatments 
given to children attending school 
and also to nonenrolled school chil-
dren who may attend the day of 
treatment, since PC is to be as inclu-
sive as operationally possible [7,84]. It 
must be remembered that delivery 
of PC can also take place outside 
of the school-based infrastructure 
in community-directed treatment 
campaigns when community drug 
distributors are responsible for pro-
viding treatment, often in a door-to-
door setting [6,85]. It is outside the 
scope of this review to address the 
relative merits of PC as delivered by 
school- or community-based plat-
forms, but it should be remembered 
that both school-teachers and com-
munity drug distributors need some 
form of basic training to be able to 
perform administration of treatment 
well [7]. With scale-up of this work 
force, often operating on a basis of 
goodwill, to maintain its integrity 
through time some consideration of 
incentive and reward is needed [2]. 
This can be in the form of simple 
per diems allowances to compensate 
for the time ‘occupied’ in delivering 
control. 
At a national level, summary statistics are typically 
presented as reported drug coverage by district then 
region, as information becomes available and this can 
be easily inspected country-by-country and year-on-
year through the WHO preventive chemotherapy data-
base [83]. The website is regularly updated presenting 
all reported information from 2006 onwards [105], with 
interactive maps, summary tabulations and graphical 
outputs that chart ongoing progress in delivery of PC, 
see Figure 1. Presently it is, however, difficult to capture 
precisely the reported treatment coverage of PZQ and 
ALB combined [6,84], however, this database will be the 
first point of call in measuring progress towards the 
2020 WHO targets where achieving treatment cover-
age of 75% is the rally point for future success [2].
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Figure 5. Chart of the relationships between height and age for drug administration.   Age 
range of pre-school-aged children, school-aged children and adults, that (B) corresponds 
to height thresholds for praziquantel administration and (C) age-range for administration of 
albendazole.
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Future perspective 
It is clear that cotreatment with PZQ and ALB 
makes sound public health sense when the practi-
calities of PC are considered in a landscape where 
schistosomiasis and STH abound. With the scale-up 
of cotreatment there are opportunities that should not 
be missed. First is that there will be tangible impacts 
upon reducing the co-morbidity of other diseases, 
which should be mindful of the positive impact 
deworming has upon HIV incidence and progression 
onto AIDS, with or without antiretroviral therapy [5]. 
At the same time with scale-up as monitored with the 
preventive chemotherapy database, vigilance for drug 
tolerant parasites should increase as there is some evi-
dence that populations of parasites already differ in 
their susceptibility to these medications. Should this 
be a major concern? While there are ongoing drug 
discovery programs for schistosomiasis and STH, 
it is unlikely that any new anthelminthics will be 
brought to market within the next decade [86–88], but 
we believe there to be ample room to explore new dos-
ing requirements that might mitigate any poor per-
formance at either standard lower 40 mg/kg dosing 
with PZQ or with single or half-tablet administration 
of ALB. There is therefore much scope for optimism 
that existing cotreatment regimes will have a solid 
and long-term impact upon reducing the burden of 
disease. 
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Executive summary
 ■ Cotreatment of children with praziquantel and albendazole is the frontline intervention against schistosomiasis and 
soil-transmitted helminthiasis, several tens of millions of children are receiving treatment.
 ■ Cotreatment is safe and is orally administered, often by nonmedical personnel, in a WHO endorsed strategy of integrated 
preventive chemotherapy for neglected tropical diseases.
 ■ Both praziquantel and albendazole are donated gratis by major pharmaceutical agencies, their scale-up in use is in line with 
WHO predictions for the 2012–2020 period.
 ■ There is scope for future optimization of cotreatment in terms of increased dosing and more frequent periodicity to 
safeguard drug(s) performance in the longer term. 
 ■ Regularly monitoring global needs and routine monitoring of drug efficacy at national levels are essential to sustain drug 
delivery and ensure an enduring impact.
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